Eosinophil persistence in vivo and sustained viability ex vivo in response to respiratory challenge with fungal allergens

Clinical and Experimental Allergy

Volumn 48, Issue 1, 2018, Pages 29-38

  Geslewitz, W E ^a   Percopo, C M ^a   Rosenberg, H F ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

animal models; asthma; eosinophils

Indexed keywords

ALLERGEN; CCL1 CHEMOKINE; CXCL13 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; FUNGUS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 5; STROMAL CELL DERIVED FACTOR 1;

ALTERNARIA ALTERNATA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; BRONCHOALVEOLAR LAVAGE FLUID; CELL SURVIVAL; CELL SUSPENSION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; EOSINOPHIL; EX VIVO STUDY; GENE DELETION; IN VIVO STUDY; LUNG LAVAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

EID: 85034769490     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.13050     Document Type: Article

References (46)

1. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13:9-22.
2. Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40:563-575.
3. Carr TF, Berdnikovs S, Simon HU, Bochner BS, Rosenwasser LJ. Eosinophilic bioactivities in severe asthma. World Allergy Organ J. 2016;9:2.
4. Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med. 2015;192:660-668.
5. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.
6. Maltby S, Tay HL, Yang M, Foster PS. Mouse models of severe asthma: understanding the mechanisms of steroid resistance, tissue remodeling and disease exacerbation. Respirology. 2017;22:874-885.
7. Kumar RK, Herbert C, Foster PS. The “classical” ovalbumin challenge model of asthma in mice. Curr Drug Targets. 2008;9:485-494.
8. Ochkur SI, Jacobsen EA, Protheroe CA, et al. Co-expression of IL-5 and eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. J Immunol. 2007;178:7879-7889.
9. Rankin JA, Picarella DE, Geba GP, et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA. 1996;93:7821-7825.
10. Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2261-2263.
11. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258-2261.
12. Ghosh S, Hoselton SA, Dorsam GP, Schuh JM. Eosinophils in fungus-associated allergic pulmonary disease. Front Pharmacol. 2013;4:8.
13. Kumar RK, Herbert C, Foster PS. Mouse models of acute exacerbations of allergic asthma. Respirology. 2016;21:842-849.
14. Kita H. ILC2s and fungal allergy. Allergol Int. 2015;64:219-226.
15. Salo PM, Arbes SJ Jr, Crockett PW, Thorne PS, Cohn RD, Zeldin DC. Exposure to multiple indoor allergens in US homes and its relationship to asthma. J Allergy Clin Immunol. 2008;121:678-684.
16. Kustrzeba-Wojcicka I, Siwak E, Terlecki G, Wolanczyk-Medrala A, Medrala W. Alternaria alternata and its allergens: a comprehensive review. Clin Rev Allergy Immunol. 2014;47:354-365.
17. Gabriel MF, Postigo I, Tomaz CT, Martinez J. Alternaria alternata allergens: markers of exposure, phylogeny and risk of fungi-induced respiratory allergy. Environ Int. 2016;89–90:71-80.
18. Havaux X, Zeine A, Dits A, Denis O. A new mouse model of lung allergy induced by the spores of Alternaria alternata and Cladosporium herbarum molds. Clin Exp Immunol. 2015;139:179-188.
19. Denis O, van den Brule S, Heymans J, et al. Chronic intranasal administration of mould spores or extracts to unsensitized mice leads to lung allergic inflammation, hyperreactivity and remodelling. Immunology. 2007;122:268-278.
20. Kim HK, Lund S, Baum R, Rosenthal P, Khorram N, Doherty TA. Innate type 2 response to Alternaria extract enhances ryegrass-induced lung inflammation. Int Arch Allergy Immunol. 2014;163:92-115.
21. hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol. 2012;188:1503-1513.
22. Anderson EL, Kobayashi T, Iijima K, Bartemes KR, Chen CC, Kita H. IL-33 mediates reactive eosinophilopoiesis in response to airborne allergen exposure. Allergy. 2016;71:977-988.
23. Valladao AC, Frevert CW, Koch LK, Campbell DJ, Ziegler SF. STAT6 regulates the development of eosinophilic versus neutrophilic asthma in response to Alternaria alternata. J Immunol. 2016;197:4541-4551.
24. Rothenberg ME, MaClean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997;185:785-90.
25. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264:713-716.
26. Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990;172:1425-1431.
27. McKenzie GJ, Emson CL, Bell SE, et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity. 1998;9:423-432.
28. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184:1397-1411.
29. hi eosinophils are a distinct subpopulation within the lungs of allergen-challenged mice. J Leukoc Biol. 2017;101:321-328.
30. Dyer KD, Garcia-Crespo KE, Killoran KE, Rosenberg HF. Antigen profiles for the quantitative assessment of eosinophils in mouse tissues by flow cytometry. J Immunol Methods. 2011;369:91-97.
31. Huang L, Gebreselassie NG, Gagliardo LF, et al. Eosinophil-derived IL-10 supports chronic nematode infection. J Immunol. 2014;193:4178-4187.
32. Lee JJ, Jacobsen EA, Ochkur SI, et al. Human versus mouse eosinophils: “that which we call an eosinophil, by any other name would stain as red”. J Allergy Clin Immunol. 2012;130:572-584.
33. Hallsworth MP, Soh CP, Twort CH, Lee TH, Hirst SJ. Cultured human airway smooth muscle cells stimulated by interleukin-1beta enhance eosinophil survival. Am J Respir Cell Mol Biol. 1998;19:910-919.
34. Ferland C, Flamand N, Davoine F, Chakir J, Laviolette M. IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration in extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression. J Immunol. 2004;173:4417-4424.
35. Geering B, Stoeckle C, Conus S, Simon HU. Living and dying for inflammation: neutrophils, eosinophils and basophils. Trends Immunol. 2013;34:398-409.
36. Esnault S, Malter JS. Granulocyte macrophage-colony-stimulating factor mRNA is stabilized in airway eosinophils and peripheral blood eosinophils activated by TNF-alpha plus fibronectin. J Immunol. 2001;266:4658-4663.
37. Esnault S, Malter JS. GM-CSF regulation in eosinophils. Arch Immunol et Therap Experimentalis. 2002;50:121-130.
38. May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. 2015;75:89-116.
39. Myrtek D, Knoll M, Matthiesen T, et al. Expression of interleukin-13 receptor alpha 1-subunit on peripheral blood eosinophils is regulated by cytokines. Immunology. 2004;112:597-604.
40. Heller NM, Gwinn WM, Donnelly RP, Constant SL, Keegan AD. IL-4 engagement of the type I IL-4 receptor complex enhances mouse eosinophil migration to eotaxin-1 in vitro. PLoS ONE. 2012;7:e39673.
41. Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170:122-131.
42. Sedgwick JB, Calhoun WJ, Vrtis RF, Bates ME, McAllister PK, Busse WW. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol. 1992;149:3710-3718.
43. Yamamoto H, Sedgwick JB, Vrtis RF, Busse WW. The effect of transendothelial migration on eosinophil function. Am J Respir Cell Mol Biol. 2000;23:379-388.
44. Percopo CM, Dyer KD, Killoran KE, Rosenberg HF. Isolation of human eosinophils: microbead method has no impact on IL-5 sustained viability. Exp Dermatol. 2010;19:467-469.
45. Lee NA, McGarry MP, Larson KA, Horton MA, Kristensen AB, Lee JJ. Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique histopathologies. J Immunol. 1997;158:1332-1344.
46. Dyer KD, Moser JM, Czapiga M, Siegel SJ, Percopo CM, Rosenberg HF. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J Immunol. 2008;181:4004-4009.